Skip to content

Brief Group Psychotherapy for Anxiety and Depression

Brief Group Psychotherapy for Anxiety and Depression: A Randomized Controlled Trial of Efficacy and Mechanisms of Change

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04489641
Enrollment
100
Registered
2020-07-28
Start date
2020-01-16
Completion date
2020-12-16
Last updated
2021-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Affective Disorder

Brief summary

The present work aims to develop a randomized clinical trial with a sample of 100 patients diagnosed with anxiety and depression in primary care. All participants are tested by several self-reports related to emotional disorders in a repeated measures design, pre and post treatment. It is our aim this study will demonstrate that brief psychological treatments should be prioritized over pharmacological treatment in Primary Care. In addition, emotional regulation will be assessed and examined as a key factor in the clinical improvement.

Interventions

Psychological treatment

DRUGMedication

Pharmacological intervention

Sponsors

Universidad de Córdoba
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Anxiety * Depression

Exclusion criteria

* Severe mental disroders * Drug abuse * Suicidal ideation/severe depression

Design outcomes

Primary

MeasureTime frameDescription
Patient Health Questionnaire-Panic Disorder (PHQ-PD)12 weeksIt measures panic disorder symotmos. Scores vould vary between 0-15 points.
Generalised Anxiety Disorder Assessment (GAD-7)12 weeksThe GAD-7 score is calculated by assigning scores of 0, 1, 2, and 3, to the response categories of 'not at all', 'several days', 'more than half the days', and 'nearly every day', respectively, and adding together the scores for the seven questions. Scores of 5, 10, and 15 are taken as the cut-off points for mild, moderate and severe anxiety, respectively. When used as a screening tool, further evaluation is recommended when the score is 10 or greater. Using the threshold score of 10, the GAD-7 has a sensitivity of 89% and a specificity of 82% for GAD.
The Patient Health Questionnaire (PHQ-9)12 weeksThe Patient Health Questionnaire (PHQ) is a self-administered version of the PRIME-MD diagnostic instrument for common mental disorders.The PHQ-9 is the depression module, which scores each of the 9 DSM-IV criteria as 0 (not at all) to 3 (nearly every day).
Beck Depression Inventory-Second Edition (BDI-II)12 weeksThe BDI-II is a widely used 21-item self-report inventory measuring the severity of depression in adolescents and adults. The BDI-II was revised in 1996 to be more consistent with DSM-IV criteria for depression. For example, individuals are asked to respond to each question based on a two-week time period rather than the one-week timeframe on the BDI. The BDI-II is widely used as an indicator of the severity of depression, but not as a diagnostic tool, and numerous studies provide evidence for its reliability and validity across different populations and cultural groups.
The Patient Health Questionnaire (PHQ-15)12 weeksIt asseses somatoform symptoms. Scores could vary between 0-30 points.

Secondary

MeasureTime frameDescription
Penn State Worry Questionnaire-Abbreviated (PSWQ-A)12 weeksIt assesses the tendency to experience worry. It consists of eight items and patients have to respond according to a 5-point Likert-type scale.
Ruminative Response Scale-10 (RRS-10)12 weeksThe RRS is the most used measure of rumination. The short version consists of 10 items that are responded on a 4-point Likert-type scale.
Metacognition Questionnaire-30 (MCQ-30)12 weeksThis instrument has been used to assess metacognitive beliefs. It consists of 30 items that are responded on a 4-point Likert-type scale.
Emotional Regulation Questionnaire (ERQ)12 weeksIt evaluates the tendency to regulate emotions. It consists of 10 items and participants have to respond according to a 7-points Likert scale. It has two subscales: reappraisal and suppression (six and four items respectively). The reappraisal subscale assesses the ability to change negative emotions while the suppression subscale assesses the tendency to repress and hide negative emotions.

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026